Diagnostic Utility of Lymphoid Enhancer Binding Factor 1 Immunohistochemistry in Small B-Cell Lymphomas

No abstract is available for this paper.

• Publication year

  2017

• Venue

  American Journal of Clinical Pathology

• Publication date

  2017-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ajcp/aqw208PMID 28395058
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues

  2017cited by this paper
• Flow cytometric analysis of lymphoid enhancer-binding factor 1 in diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma.

  2015cited by this paper
• LEF1: a highly specific marker for the diagnosis of chronic lymphocytic B cell leukaemia/small lymphocytic B cell lymphoma

  2015cited by this paper
• Characterization of LEF1 High Expression and Novel Mutations in Adult Acute Lymphoblastic Leukemia

  2015cited by this paper
• A comparative analysis of LEF-1 in odontogenic and salivary tumors.

  2015cited by this paper
• LEF-1 is Frequently Expressed in Colorectal Carcinoma and Not in Other Gastrointestinal Tract Adenocarcinomas: An Immunohistochemical Survey of 602 Gastrointestinal Tract Neoplasms

  2014cited by this paper
• Overexpression of Lymphoid Enhancer-Binding Factor 1 (LEF1) in solid-pseudopapillary neoplasms of the pancreas

  2014cited by this paper
• Increased LEF1 Expression and Decreased Notch2 Expression Are Strong Predictors of Poor Outcomes in Colorectal Cancer Patients

  2013cited by this paper
• Aberrant lymphocyte enhancer-binding factor 1 expression is characteristic for sporadic Burkitt's lymphoma.

  2013cited by this paper
• B-cell receptor signaling in chronic lymphocytic leukemia.

  2011cited by this paper
• Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia/small lymphocytic lymphoma in small B-cell lymphomas

  2011cited by this paper
• LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis.

  2010cited by this paper
• Targeting the WNT/beta-catenin/TCF/LEF1 axis in solid and haematological cancers: Multiplicity of therapeutic options.

  2009cited by this paper
• Optimal processing of bone marrow trephine biopsy: the Hammersmith Protocol

  2006cited by this paper
• Diversity of LEF/TCF action in development and disease

  2006cited by this paper
• The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma.

  2006cited by this paper
• WNT signalling and haematopoiesis: a WNT–WNT situation

  2005cited by this paper
• Loss of expression of the WNT/beta-catenin-signaling pathway transcription factors lymphoid enhancer factor-1 (LEF-1) and T cell factor-1 (TCF-1) in a subset of peripheral T cell lymphomas.

  2003cited by this paper
• Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells

  2001cited by this paper

• Identifying genes and pathways in familial lymphoid cancers using whole exome sequencing.

  2026cites this paper
• Autoimmune Hemolytic Anemia Occurring One Year Before Acute Leukemic Manifestation of Lymphoma with a Chronic Lymphocytic Leukemia Immunophenotype.

  2025cites this paper
• The Role of LEF1 Protein in Chronic Lymphocytic Leukemia and Different Treatment Methods

  2025cites this paper
• Marginal Zone Lymphoma in a Case of Hidradenitis Suppurativa Treated With Adalimumab Therapy

  2025cites this paper
• Lymphoid enhancer-binding factor 1 (LEF1): a reliable immunohistochemical predictive marker for WNT-activated medulloblastoma

  2025cites this paper
• Diagnostic utility of lymphocyte enhancer factor 1 in aggressive B-cell lymphoma with MYC rearrangement.

  2025cites this paper
• From the archives of MD Anderson Cancer Center: Composite mantle cell lymphoma and lymphoplasmacytic lymphoma involving bone marrow at presentation.

  2024cites this paper
• Current Landscape of Ancillary Diagnostic Testing in Chronic Lymphocytic Leukemia.

  2023cites this paper
• Evidence-Based Management of Chronic Lymphocytic Leukemia: Consensus Statements from the Gulf Region

  2023cites this paper
• LEF1 enhances β-catenin transactivation through IDR-dependent liquid–liquid phase separation

  2023cites this paper
• Systemic Abscopal Effect of Low-dose Radiotherapy (2 Gy ×2) against Palatine Tonsil Follicular Lymphoma

  2022cites this paper
• Lymphoplasmacytic lymphoma and a CD5+ lymphoproliferative process presenting as composite disease in the bone marrow: a report of two cases

  2021cites this paper
• Additional characterization of LEF1 expression in nodular lymphocyte predominant Hodgkin lymphoma and classic Hodgkin lymphoma.

  2021cites this paper
• Subgroup-specific gene expression profiles and mixed epistasis in chronic lymphocytic leukemia

  2021cites this paper
• DNA methylation-based classification of small B-cell lymphomas: a proof-of-principle study.

  2021cites this paper
• LncRNA landscape analysis identified LncRNA LEF-AS1 as an oncogene that upregulates LEF1 and promotes survival in chronic lymphocytic leukemia.

  2021cites this paper
• Recent advances upper gastrointestinal lymphomas: molecular updates and diagnostic implications

  2020cites this paper
• Small B-Cell Lymphomas With and Without Plasmacytic Differentiation

  2020cites this paper
• Differential diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma and other indolent lymphomas, including mantle cell lymphoma

  2020cites this paper
• Immunohistochemical Expression of Lymphoid Enhancer Binding Factor 1 in CD5-Positive Marginal Zone, Lymphoplasmacytic, and Follicular Lymphomas.

  2020cites this paper
• Lymphoid enhancer binding factor 1 (LEF1) expression is significantly higher in Hodgkin lymphoma associated with Richter syndrome relative to de novo classic Hodgkin lymphoma.

  2020cites this paper
• Malignant Hematopoietic Disorders of the Mediastinum

  2020cites this paper
• Downregulation of Lymphoid enhancer‐binding factor 1 (LEF‐1) expression (by immunohistochemistry and/ flow cytometry) in chronic Lymphocytic Leukemia with atypical immunophenotypic and cytologic features

  2020cites this paper
• Lymphoid enhancer-binding factor 1 (LEF-1): a favorable prognostic factor in adult acute myeloid leukemia in Egyptian patients

  2020cites this paper
• Splenic Marginal Zone Lymphoma and Other Small B-Cell Lymphomas

  2020cites this paper
• Diagnostic Pathology of Hematopoietic Disorders of Spleen and Liver

  2020cites this paper
• MMP 18-1 Flow Cytometric Analysis of LEF 1 for Distinguishing Chronic Lymphocytic Leukemia from other CD 5-positive B-Cell Lymphoproliferative Disorders

  2019cites this paper
• MicroRNA-6852 suppresses glioma A172 cell proliferation and invasion by targeting LEF1.

  2019cites this paper
• Incidental splenic findings in pancreatosplenectomy specimens resected for primary pancreatic lesions

  2019cites this paper
• Expression of LEF1 and TCF1 (TCF7) proteins associates with clinical progression of nasopharyngeal carcinoma

  2019cites this paper
• Pearls and pitfalls in the diagnostic workup of small lymph node biopsies

  2019cites this paper
• The Role of Expression of Lymphoid Enhancer-Binding Factor-1 (LEF-1) in Patients with Chronic Lymphocytic Leukemia

  2018cites this paper